Vincent Trebosc

Microbiologist interested in drug discovery, AMR, virulence and synthetic biology (and wine and rugby and..) 🇨🇵🇨🇭

[NCCR AntiResist @NCCR_AntiResist]

📢 🚀 We are hiring! 🔎 🙏

Scientific Officer (80-100%)

👉A rare opportunity to play a central part in coordinating the research activities of NCCR AntiResist.

Come and join us! 👉https://t.co/wLisZaEcCA

#TransformingAntimicrobialResearch

#hiring #job #science #research

[Vincent Trebosc @V_Trebosc]

#JobAlert Research Scientist PK/PD in our R&D team at @Bioversys Lille (France) #AMR
https://t.co/YtfhWTYGDN

[David Grainger @GraingerLab]

Well done @mulecc - your PhD work just published 😀https://t.co/8FF3Q00YGu
I think we've only scratched the surface with this... H-NS allowing bacteria to direct their own evolution. Exciting times ahead...

[Hirsch Lab @HirschLab]

We are seeking excellent candidates for three PostDoc positions at the Department of Drug Design and Optimization, HIPS. If you have a strong background in MedChem and synthesis of bioactive small molecules, then feel free to apply!
https://t.co/prbnOfPKtN

[ASM @ASMicrobiology]

Bacteria often adapt to stress through 2-component regulatory systems (TCS). In Klebsiella pneumoniae, the EnvZ/OmpR TCS facilitates lung infection by transcriptionally regulating key virulence factors. Read the article in @JournalSpectrum: https://t.co/4YdPs415z3

[Nature Microbiology @NatureMicrobiol]

Out now! In vitro models that mimic within patient conditions should be used to revitalize antibiotic discovery and development https://t.co/RNoGDRx2vP

[NCCR AntiResist @NCCR_AntiResist]

Announcing the conference: "New Approaches to Combat Antibiotic-Resistant Bacteria" for world-leading, novel AMR science. 🦠👩‍🔬🧑‍🔬

🗓️ 9-13 June 2024
🏡 Ascona, Switzerland

Now open for abstract submissions!

#AMR #TransformingAntimicrobialResearch

https://t.co/gDLlLoan4g

[mark belan | science illustrator + info designer @markabelan]

The Many Shapes of Bacteria

#infographic #bacteria #microbes #biology #science #design #illustration #art #sciart #shapes #geometry #microbiology

[Francois Lebreton @Fr_Lebreton]

If you are like me and do everything at the last minute, now is the time to apply to #AMR ICARe course (Oct 7-15). Full program is available at https://t.co/C3VAWeiknW and deadline for student application is June 21! @sylvainbrisse and I will teach genomic epi + hands on bioinf

[Centre d'infection et d'immunité de Lille @CIILofficiel]

👇Check it out: a call for a Junior Group Leader
on Infectious diseases and/or antimicrobial resistance
Institut Pasteur de Lille, France

[Pierre Jacquel @pierre_jacquel2]

Rappel pour nos amis chercheurs et étudiants : il est INTERDIT d'utiliser ce site qui permet d'accéder à tous les articles de recherche gratuitement !

Ce site est souvent bloqué par les fournisseurs internet, il est aussi interdit de contourner le blocage avec cette méthode. 🧵

[AMR Action Fund @AMRActionFund]

"In just about every other therapeutic area, investors and drugmakers can rely on the market to reward the development of impactful medicines through strong sales," writes @deepalimpatel. "Not so with antimicrobials." #AMR https://t.co/AxdTh2DQV4 via @EFPIA

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

We're hiring! 📢

Would you like to work in a multicultural and dynamic team committed to addressing the growing threat of #antibioticresistance?

If so, this is for you! 👇👇
https://t.co/3FCIuxYkg7

[Valeria Gigante @valeria_gigante]

⏰Consultancy opportunity to work on the antibacterial pipeline review. Closing tomorrow!
Please share in your network!
@HatimSati @WHO

[ANTIBIOTIC CellMAP @TRR261]

TRR261 announces and recommends the ICARe 2023 course!

[Vincent Trebosc @V_Trebosc]

And big thanks to @AnnaCVetter for the cool accumulation work!

[Vincent Trebosc @V_Trebosc]

Happy to share this new piece in the characterization of FhuE mediated hyperactivity of rifabutin against A. baumannii. @NicolasWilland
@univ_lille @Helmholtz_HZI @Bioversys #AMR https://t.co/VBFG8Mdqhw

[AMR Action Fund @AMRActionFund]

“I personally find it unacceptable that we would have drugs in hand that help a significant number of patients from not passing away — and we have to drop this for financial reasons, rather than scientific ones.” The unfortunate reality of the abx market
https://t.co/SCDmWccbtB

[BioVersys @Bioversys]

#BioVersys is delighted to announce the 1st patient dosed in Phase 2a clinical trial with BVL-GSK098. The trial is being run in South Africa with our partners @taskapplied, and in collaboration with @GSK. This study receives valuable funding from @EDCTP. https://t.co/6xFUGTEgTe

[AMR Action Fund @AMRActionFund]

We are thrilled to announce our investment into @BioVersys! The antibiotics they are developing target some of the highest-priority drug-resistant pathogens and could deliver significant benefits to patients suffering from life-threatening infections. https://t.co/GunkoIp57g #AMR